Upcoming AWS Coverage on Incyte Post-Earnings Results

LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. blog coverage looks at the headline from Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) as the Company announced on January 27, 2017, that it had chosen Worldwide Clinical Trials as its CRO (Clinical Research Organization) for the AURORA Phase-3 Study of Voclosporin for the Treatment of Active Lupus Nephritis. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Aurinia Pharma’s competitors within the Biotechnology space, Incyte Corp. (NASDAQ: INCY), announced on January 24, 2017, that it will release its Q4 and year end 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, February 14, 2017. AWS will be initiating a research report on Incyte in the coming days.

Today, AWS is promoting its blog coverage on AUPH; touching on INCY. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=AUPH

http://www.activewallst.com/registration-3/?symbol=INCY

Victoria, British Columbia based Aurinia is a clinical biopharmaceutical company that works to develop and commercialize therapies to treat serious diseases with high unmet medical need. Aurinia is developing an investigational drug for the treatment of Lupus Nephritis (LN).

Worldwide Clinical Trials is a full-service contract research organization (CRO) that partners with pharmaceutical and biotechnology companies and assists them across the various stages of drug development from discovery to clinical development and commercialization. They are equipped to cover a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID) and rare diseases.

Commenting on the partnership, Charles Rowland, CEO of Aurinia said:

“We are thrilled to partner with Worldwide to support the AURORA Phase-3 clinical trial. We are rapidly moving forward with our plans to bring this important therapy to market for patients living with this devastating disease, and Worldwide’s deep expertise and capabilities in managing pivotal trials will be a tremendous asset to us.”

Peter Benton, President and CEO of Worldwide Clinical Trials, added:

“Our entire Worldwide team is delighted to have been selected as Aurinia’s CRO partner to advance Voclosporin, which has the potential to become the first FDA-approved treatment for LN.”

About the disease – Lupus Nephritis

Lupus also known as System Lupus Erythematosus (SLE) is a chronic, complex and often disabling disorder that affects more than 500,000 people in the US, mostly women. SLE is an extremely heterogeneous disease which can affect the heart, lungs, skin, joints, vascular system, and kidneys.

Lupus Nephritis (LN) in an inflammation of the kidney that represents a serious progression of SLE. It is estimated that as many as 60% of all SLE patients have clinical LN requiring treatment. LN can lead to permanent and irreversible tissue damage within the kidney, resulting in end-stage renal disease, which makes it a serious and potentially life-threatening condition. Currently, there is no FDA approved therapy for treatment for LN.

About the drug Voclosporin

Voclosporin is an investigational drug and a novel and potentially best-in-class calcineurin inhibitor (CNI). Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the US Food & Drug Administration (FDA). It has the potential to become the first approved treatment for LN in the US and Europe. The Company expects that once the drug gets FDA approval it would enjoy patent protection in US and other markets including Europe and Japan till October 2027.

The AURORA Study

The AURORA is a 52-week global double-blind Phase-3 study. The aim of the study is to investigate whether Voclosporin, added to the standard of care treatment in active lupus nephritis (LN), is able to reduce disease activity over a treatment period of 24 weeks. The trial is being conducted on approximately 320 patients. The primary aim of the trial is that by the end of week 24, participants in the trial should achieve renal response.

Brief Background and Way Forward

In November 2016, Aurinia had announced that it planned to initiate a single, Phase-3 clinical trial (AURORA) which is designed similarly to that of their ongoing AURA clinical trial. The single Phase-3 clinical trial is for use of Voclosporin in the treatment of lupus nephritis (LN). The announcement was made following Aurinia’s successful End of Phase-2 meeting with the US FDA Division of Pulmonary, Allergy and Rheumatology Products. On completing the Phase-3 trials, Aurinia plans to use data from both the AURA and AURORA trials for the applying for a New Drug Application (NDA). Since that time, Aurinia is on a tight schedule to ensure that its team is ready to execute a successful clinical trial. It focused on finalizing the study protocol and regulatory submissions along with site selection and necessary investments so that it can reach its goal. Aurinia has plans to start the Phase-3 AURORA trials in Q2 2017.

The selection of Worldwide as its CRO is the first step in this direction. With the partnership with Worldwide Aurinia will be able to move forward on the 52-week Phase-3 AURORA trials on approximately 320 patients. The experts at Worldwide will work closely with Aurinia’s Robert Huizinga, VP of Clinical Development and Rashieda Gluck, VP of Clinical Operations, for completing the AURORA study successfully.

The estimated date of completion of the final data collection of the study to measure the primary outcome is December 2019. The study is expected to be completed by March 2020.

Stock Performance

Aurinia Pharma’s share price finished last Friday’s trading session at $3.22, jumping 5.57%. A total volume of 7.00 million shares exchanged hands, which was higher than the 3 months average volume of 1.57 million shares. The stock has surged 50.47% and 54.07% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have soared 53.33%. The stock currently has a market cap of $124.92 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453788

Upcoming AWS Coverage on Bank of Hawaii Post-Earnings Results

LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. announces its post-earnings coverage on Zions Bancorp (NASDAQ: ZION). The Company posted its financial results for the fourth quarter fiscal 2016 (Q4 FY16) and full year 2016 (FY16) on January 23, 2017. The Salt Lake City, Utah-based company’s diluted EPS surged 40% y-o-y, outperforming Wall Street’s estimates. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Zions Bancorp’s competitors within the Regional – Pacific Banks space, Bank of Hawaii Corp. (NYSE: BOH), reported its 2016 Financial Results on January 23, 2017. AWS will be initiating a research report on Bank of Hawaii in the coming days.

Today, AWS is promoting its earnings coverage on ZION; touching on BOH. Get our free coverage by signing up to:

http://www.activewallst.com/registration-3/?symbol=ZION

http://www.activewallst.com/registration-3/?symbol=BOH

Earnings Reviewed

During Q4 FY16, Zions’ total interest income grew 6% to $501.77 million in Q4 FY16 from $473.56 million in Q4 FY15. The Company’s total interest expenses fell to $21.30 million in Q4 FY16 from $24.73 million in Q4 FY15. Zions’ net interest income also increased 6.9% during the reported quarter to $480.47 million from $448.83 million in Q4 FY15. Furthermore, total non-interest income increased to $128.24 million in Q4 FY16 from $118.64 million in the year ago same quarter.

The financial holding Company reported net income applicable to common shareholders of $124.99 million, or $0.60 per diluted share, in Q4 FY16 compared to $88.20 million, or $0.43 per diluted share, in Q4 FY15. Wall Street had expected the Company to report adjusted earnings of $0.52 per diluted share.

In FY16, Zions’ net interest income increased to $1.87 billion from $1.72 billion in FY15. The Company’s total noninterest income also improved during FY16 to $515.61 million from $357.24 million in the previous year. Furthermore, net income available to common equity for the reported quarter came in at $411.31 million, or $1.99 per diluted share, compared to $246.61 million, or $1.20 per diluted share in FY15.

Earnings Metrics

During the reported quarter, the Company’s return on average assets improved to 0.89%, from 0.68% in the prior year’s comparable quarter. The return on average common equity came in at 7.10% in Q4 FY16, which came in above 5.17% reported in the year ago same period. Moreover, tangible return on average tangible common equity for the reported quarter was 8.40% in Q4 FY16 compared to 6.20% in the prior year’s corresponding quarter.

The Company’s efficiency ratio was 64.5% in Q4 FY16 compared to 69.6% in Q4 FY15. Net interest margin rose during Q4 FY16 to 3.37% from 3.23% in Q4 FY15. The tangible common equity ratio was 9.49% at December 31, 2016, compared to 9.63% as on December 31, 2015. During Q4 FY16, Basel III common equity tier 1 capital ratio was 12.1%, versus 12.2% in the prior year’s comparable quarter. Additionally, Basel III tier 1 leverage ratio stood at 11.1% as on December 31, 2016, compared to 11.3% as on December 31, 2015.

Balance Sheet Analyzed

Zions’ average total loans held for investment balance at the end of Q4 FY15 was $42.64 billion compared to $40.35 billion at the end of last year’s corresponding quarter. In Q4 FY14, the average yield on total loans held for investment was 4.11% compared to 4.24% in Q4 FY15. Total average interest-earning assets for the quarter ended December 31, 2016 were $57.55 billion versus $55.69 billion recorded in the prior year’s same period. In Q4 FY16, spread on average interest-bearing funds during was 3.24% compared to 3.07% in Q4 FY15. Furthermore, average total deposits increased $1.5 billion in Q4 FY16 to $52.2 billion.

The Company had total non-performing assets of $572.91 million at December 31, 2016, compared to $356.95 million as on December 31, 2015. Non-performing assets as a percent of loans and leases and other real estate owned was 1.34% at December 31, 2016, up 47 basis points from 0.87% as on December 31, 2015. However, provision for credit losses decline to $0.609 million from $16.15 million in the year ago same quarter.

Dividend and Share Repurchase

In a separate press release on January 27, 2017, Zions’ Board of Directors announced a regular quarterly dividend of $0.08 per common share. The dividend is payable February 23, 2017 to shareholders of record on February 16, 2017.

During FY16, Zions continued its stock buyback program and repurchased $45 million of its stock during the reported quarter at an average price of $31.69 per share. Furthermore, the Company has repurchased $90 million of its stock since July 01, 2016 at an average price of $31.15 per share and has a balance of $90 million of buyback capacity remaining in the 2016 capital plan, ending June 2017.

Stock Performance

Last Friday, January 27, 2017, the stock closed the trading session at $43.12, marginally falling 0.81% from its previous closing price of $43.47. A total volume of 1.97 million shares have exchanged hands. Zions Bancorp’s stock price advanced 34.45% in the last three months, 54.00% in the past six months, and 96.65% in the previous twelve months. The Company’s shares are trading at a PE ratio of 23.54 and have a dividend yield of 0.74%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453785

Upcoming AWS Coverage on Old Dominion Freight Line Post-Earnings Results

LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. announces its post-earnings coverage on J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT). The Company posted its financial results for the fourth quarter and full year 2016 on January 19, 2017. The transportation Company’s sales numbers outperformed market expectations, while earnings lagged behind. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of J.B. Hunt Transport Services’ competitors within the Trucking space, Old Dominion Freight Line, Inc. (NASDAQ: ODFL), announced on January 12, 2017, that it will release its Q4 and year-end 2016 financial results before opening of trading on Thursday, February 02, 2017. The Company will also hold a conference call to discuss its financial results and outlook at 10:00 a.m. ET on the same day. AWS will be initiating a research report on Old Dominion Freight Line in the coming days.

Today, AWS is promoting its earnings coverage on JBHT; touching on ODFL. Get our free coverage by signing up to:

http://www.activewallst.com/registration-3/?symbol=JBHT

http://www.activewallst.com/registration-3/?symbol=ODFL

Earnings Reviewed

For the fourth quarter ended December 31, 2016, J.B. Hunt’s total operating revenue was $1.72 billion compared to $1.62 billion for Q4 FY15. The current quarter total operating revenue, excluding fuel surcharges, increased 6% versus the comparable quarter 2015. The Company’s revenue numbers were above analysts’ forecasts of $1.71 billion. For FY16, J.B. Hunt reported revenue of $6.56 billion compared to revenue of $6.19 billion for FY15.

The Company’s operating income for Q4 FY16 increased to $194.4 million versus $192.9 million for Q4 FY15. The increase was primarily attributed to higher revenue in JBI, DCS, and ICS business segments and a $15.2 million pre-tax, one-time benefit recorded to reflect a change in employee paid time off policy.

J.B. Hunt reported Q4 2016 net earnings of $117.6 million, or diluted earnings per share of $1.05, versus Q4 2015 net earnings of $116.7 million, or $1.01 per diluted share. The reported quarter net earnings included a one-time after tax benefit of $9.5 million, or $0.08 per diluted share, for a change in the Company’s paid time off policy. The Company attributed the increase in earnings to growth in revenue, the paid time off policy change benefit, and a lower effective income tax rate. J.B. Hunt’s earnings, adjusted for pre-tax gains, came in at $0.97 per share, below Wall Street’s forecasts of $1.00 per share.

Segment Information

Intermodal (JBI)

J.B. Hunt’s Intermodal segment reported revenue of $998 million for Q4 2016, up 3% y-o-y, reflecting volume growth of 5% and a 2% decrease in revenue per load which is the combination of freight mix, customer rate increases, and fuel surcharges. The division recorded operating income of $124 million, down 3% on a y-o-y basis. The division’s Eastern network loads were flat and transcontinental loads increased 9% compared to Q4 2015. The current period ended with approximately 84,600 units of trailing capacity and approximately 5,280 power units in the dray fleet.

Dedicated Contract Services (DCS)

During Q4 2016, revenue from J.B. Hunt’s DCS segment grew 8% to $398 million, while its operating income soared 37% to $57.5 million. The division’s productivity (revenue per truck per week) increased approximately 5% versus 2015. Productivity excluding fuel surcharge revenue increased approximately 3% from a year ago primarily from improved integration of assets between customer accounts, fewer unseated trucks, increased customer supply chain fluidity, and customer rate increases. A y-o-y net additional 193 revenue producing trucks, 29 net additions compared to Q3 2016, were in the fleet by the end of Q4 2016.

Integrated Capacity Solutions (ICS)

For Q4 2016, J.B. Hunt’s ICS segment registered revenue growth of 22% to $232 million, primarily due to a 38% increase in volume offset by a 12% decrease in revenue per load and freight mix changes driven by customer demand. The segment’s Q4 2016 operating income totaled $6.1 million; down 52%, primarily due to a lower gross profit margin, increased claim costs, higher technology costs, and increased personnel costs which was partially offset with approximately $1.0 million from the change in paid time off policy. ICS segment’s gross profit margin decreased to 12.9% in Q4 2016 from 16.0% in Q4 2015, primarily from new customer rates implemented during the reported quarter and lower spot. Total branches at the end of the period grew to 42 from 34 at the end of the same period in 2015.

Truck (JBT)

J.B. Hunt’s Truck segment reported revenue of $96 million, down 3% on a y-o-y basis. The segment’s revenue excluding fuel surcharges also decreased 3% primarily from a 3% decrease in rate per mile due to core customer rate decreases of approximately 1.4% and freight mix changes compared to Q4 2015. The Truck unit’s Q4 2016 operating income declined 35% to $ 6.8 million. At the end of Q4 2016, JBT operated 2,128 tractors compared to 2,149 a year ago.

Cash Flow and Capitalization

At December 31, 2016, J.B. Hunt had total debt outstanding of $986 million on various debt instruments compared to $998 million at December 31, 2015. The Company’s net capital expenditures for FY16 approximated $485 million versus $556 million in 2015. At December 31, 2016, J.B. Hunt had cash and cash equivalents of $6.4 million.

In Q4 2016, J.B. Hunt purchased 880,000 shares of its common stock for approximately $75 million. At December 31, 2016, the Company had approximately $201 million remaining under its share repurchase authorization.

On January 25, 2017, J.B. Hunt announced that its Board of Directors has declared the regular quarterly dividend on its common stock of $ 0.23 per common share, which is an approximate 4.5% increase from the previous quarterly dividend of $0.22 per share. The dividend is payable to stockholders of record on February 10, 2017. The dividend will be paid on February 24, 2017.

Stock Performance

At the closing bell, on Friday, January 27, 2017, J.B. Hunt’s stock closed the trading session at $98.87, marginally rising 0.11% from its previous closing price of $98.76. A total volume of 605.19 thousand shares have exchanged hands. J.B. Hunt’s stock price advanced 23.46% in the last three months, 19.52% in the past six months, and 42.29% in the previous twelve months. The Company’s shares are trading at a PE ratio of 25.93 and have a dividend yield of 0.89%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453784

Drug Overdose is the Leading Cause of Accidental Death in the United States

UNION, NJ / ACCESSWIRE / January 30, 2017 / Opioids are driving this national tragedy, with nearly 19,000 overdose deaths related to pain relievers and more than 10,500 related to heroin in 2014 alone. Four out of five heroin users began with prescription painkillers. As the rate of opioid abuse continues to escalate, so does the rate of heroin abuse. Today, the country is experiencing a frightening surge in opioid abuse and overdose deaths.

People Using Heroin the Most

Heroin use has increased across nearly every demographic group. Surprisingly, the groups that traditionally were the least likely to use heroin – women, people with higher incomes, and the privately insured – have seen the greatest increases. High school students, especially seniors, are at a greater risk of abusing opioids and heroin than ever, with 12.4% of seniors admitting to lifetime nonmedical opioid use. According to surveys, Caucasian high school students were more likely to report nonmedical opioid and heroin use than African American and Latino students were. However, Caucasian students were less likely than the other two groups to use heroin without nonmedical opioid use.

People between the ages of 18 and 25 are most at risk of heroin addiction. Heroin use among this age bracket has more than doubled in the last 10 years. This increase may be attributable to the easy access of prescription painkillers and heroin, as well as heroin’s lower cost. As more young people misuse prescription opioids with the impression that they are safer than illicit drugs, the number of heroin users likewise escalates. Other risk factors for heroin abuse include:

Prescription painkiller addiction
Cocaine addiction
Alcohol addiction
Lack of insurance or Medicaid
Living in a large metropolitan region
Male non-Hispanic demographic

Urban areas still have the highest rates of heroin abuse, but rural communities are quickly catching up. The influx in heroin and opioid abusers in rural areas across America has led policymakers to try to make addiction treatment centers more easily available to citizens who live far away from the nearest metropolitan help center.

Areas with the Most Rampant Heroin Use

The Midwest has seen the most drastic increase in heroin abuse, closely rivaled by the Northeast. Nearly every state has experienced a rise in heroin use in the last decade, but some states are seeing higher rates of abuse than others are. Ten states saw drug overdose death rates that exceeded 20 deaths per 100,000 people in 2014 – the highest year on record for the number of overdose deaths – the top three of which were West Virginia, New Mexico, and New Hampshire. West Virginia had 35 drug overdose deaths per 100,000 residents, an increase of 437% since 2004.

Death Toll and Other Costs

An estimated 467,000 people are currently addicted to heroin in the United States. The consequences of this significant issue are immense and devastating. The number of accidental overdose deaths has more than quadrupled since 1999, resulting in an unquantifiable loss in premature deaths. The U.S. takes a hit for lost productivity costs, health care costs, unemployment, crime rates, homelessness, and treatment center costs. The estimated annual cost to American of all drug abuse is $786 billion.

Heroin use also affects unborn children, leading to an increase in societal medical costs. Neonatal abstinence syndrome (NAS) greatly increases the length of a newborn’s hospital stay, from an average of 2.1 days to 16.9 days. This increases the cost of birth from $3,500 on average to $66,700 per child born with NAS. While NAS typically does not have lasting health effects, babies born with drug dependencies have to undergo the painful symptoms of withdrawal, just as an adult would.

The Future of America’s Heroin Epidemic

The issue of substance abuse in America involves many facets of public policy, including border security, the criminal justice system, and health care regulations. The federal government provides educational training to health care providers so they prescribe the appropriate amount of painkillers. Providers must also educate patients on the risks of becoming addicted to prescription opioids and their use as gateway drugs for heroin and other substances.

Increasing access to treatment centers is a top priority, as there is currently a deficit between the number of beds available and the number of addicts seeking treatment. Researchers need more funding to create pain medications that are less prone to addiction and create treatments for heroin addictions that are more effective.

Summit Behavioral Health – Serenity At Summit

Detox Treatment
1000 Galloping Hill Road
Union, NJ 07083

Source: https://www.serenityatsummit.com/blog/tracking-numbers-regarding-u-s-heroin-epidemic/

SOURCE: Summit Behavioral Health via Submit Press Release 123

ReleaseID: 453682

Upcoming AWS Coverage on Oceaneering International Post-Earnings Results

LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. announces its post-earnings coverage on Halliburton Co. (NYSE: HAL). The Company released its financial results for the fourth quarter and full year 2016 (FY16) on January 23, 2017. The world’s No. 2 oilfield services provider swung to its first quarterly operating profit in North America in a year. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Halliburton’s competitors within the Oil & Gas Equipment & Services space, Oceaneering International, Inc. (NYSE: OII), announced on January 10, 2017, that it will report its financial results for Q4 and full year 2016 on Wednesday, February 08, 2017, after the close of trading on the NYSE. AWS will be initiating a research report on Oceaneering International in the coming days.

Today, AWS is promoting its earnings coverage on HAL; touching on OII. Get our free coverage by signing up to:

http://www.activewallst.com/registration-3/?symbol=HAL

http://www.activewallst.com/registration-3/?symbol=OII

Earnings Reviewed

For the three months ended on December 31, 2016, Halliburton reported total revenue of $4.02 billion, which increased 5% from revenue of $3.8 billion in Q3 2016. The Company’s reported number missed analysts’ estimates of $4.09 billion of sales. For FY16, Halliburton reported total revenue of $15.9 billion, down $7.7 billion, or 33% from FY15.

For Q4 2016, Halliburton reported operating income $53 million. The Company’s adjusted operating income for the reported quarter was $276 million compared to operating income of $128 million for Q3 2016, which did not include any impairment or other charges. For FY16, Halliburton posted operating loss of $6.8 billion compared to reported operating loss of $165 million for FY15. Excluding special items, adjusted operating income for FY16 was $690 million compared to adjusted operating income of $2.3 billion for FY15. The Company attributed the decline in revenue and operating results during FY16 on impact of lower commodity prices creating widespread pricing pressure and activity reductions on a global basis.

For Q4 2016, Halliburton announced a loss from continuing operations of $149 million, or $0.17 per diluted share. Adjusted income from continuing operations for the reported quarter, excluding impairments and other charges and a class action lawsuit settlement, was $35 million, or $0.04 per diluted share, compared to income from continuing operations for Q3 2016 of $6 million, or $0.01 per diluted share. The Company’s earnings number outperformed analysts’ estimates of $0.02 per share.

Geographic Regions

Halliburton’s revenue from North America in Q4 2016 was $1.8 billion, a 9% sequential increase, relative to a 23% increase in average US rig count. Operating results improved by $94 million from a loss of $66 million in Q3 2016 to income of $28 million in the reported quarter, driven primarily by increased pricing and utilization throughout the United States land sector and effective cost management. The revenue from the North American region accounted for approximately 44.8% of Company’s overall revenue.

During Q4 2016, The Company’s international revenue totaled $2.2 billion, up 2% on a sequential basis, driven primarily by improved activity in Production Enhancement, Landmark, and Consulting and Project Management. International region generated operating income was $305 million in the reported quarter, a 27% increase compared to Q3 2016. Operating results improved due to software sales and increased onshore activity as well as continued expense reductions.

Halliburton’s revenue from Latin America was $428 million, higher by 3% sequentially, with operating income of $30 million, a $19 million increase sequentially. These increases were largely a result of increased activity in Colombia and Argentina and year-end software sales in Mexico and Venezuela.
Europe/Africa/CIS revenue in Q4 2016 was $676 million, a 9% decrease sequentially, with operating income of $72 million, down 5% sequentially, primarily driven by weather-related reduced activity in the North Sea and Russia. These decreases were partially offset by improved activity in Nigeria and Egypt.

Halliburton’s revenue from Middle East/Asia revenue in Q4 2016 totaled $1.1 billion, a 10% increase sequentially, with operating income of $203 million, a 32% increase sequentially. These increases were driven primarily by increased completion tools sales and project management services across the region.

Operating Segments

Halliburton’s Completion and Production revenue in Q4 2016 was $2.3 billion, an increase of $92 million, or 4% from Q3 2016, while operating income was $85 million, a $61 million improvement, primarily due to improved pressure pumping pricing and utilization in the United States land market and higher completion tools sales in the Gulf of Mexico.

Drilling and Evaluation

For Q4 2016, the Company’s Drilling and Evaluation revenue registered a 6% growth sequentially to $1.8 billion, while operating income surged 64% to $248 million. These improvements were driven by year-end software sales, improved drilling activity in US land, increased Consulting and Project Management activity in Sub Saharan Africa, and the Middle East, and improved Testing and Subsea activity internationally.

Corporate and Other

In December 2016, Halliburton reached an agreement in principle to settle the Erica P. John Fund class action lawsuit that has been pending for over 14 years. As a result, Halliburton incurred a charge of $54 million during Q4 2016, which is included in Corporate and other.

Balance Sheet

During Q4 2016, Halliburton generated $720 million of cash, improving its cash position at year-end to $4 billion. The Company improved its days’ sales outstanding in the quarter by 10 days while its days of inventory dropped by six days. Halliburton noted that it reduced its capital expenditures and exited the year ending 2016 with a total CapEx spending of approximately $800 million. The Company’s current guidance for FY17 capital expenditures is $1 billion.

Stock Performance

Halliburton’s share price finished last Friday’s trading session at $58.21, slightly advancing 0.26%. A total volume of 6.89 million shares exchanged hands, which was higher than the 3 months’ average volume of 8.42 million shares. The stock has surged 37.13% and 94.49% in the last six months and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 7.62%. The stock has a dividend yield of 1.24%. At the closing price on Friday, the firm registered a market cap of $50.18 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453794

Upcoming AWS Coverage on Alexion Pharmaceuticals Post-Earnings Results

LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. blog coverage looks at the headline from Amgen Inc. (NYSE: AMGN) as the Company announced on January 27, 2017, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 501. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Amgen’s competitors within the Biotechnology space, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), announced on January 26, 2017, that it will report its financial results for Q4 and full year ended December 31, 2016 on Thursday, February 16, 2017 before the US financial markets open. Following the release of the financial results, Alexion’s management will hold a conference call and audio webcast on Thursday, February 16, 2017, at 10:00 a.m. ET. AWS will be initiating a research report on Alexion Pharma in the coming days.

Today, AWS is promoting its blog coverage on AMGN; touching on ALXN. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=AMGN

http://www.activewallst.com/registration-3/?symbol=ALXN

Approval for Available Indications

Amgen stated that CHMP has recommended ABP 501 for approval for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe chronic plaque psoriasis, moderate-to-severe hidradenitis suppurativa, non-infectious intermediate, posterior and panuveitis, moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis. The CHMP opinion also recommends approval for the treatment of certain paediatric inflammatory diseases, including moderate-to-severe Crohn’s disease, severe chronic plaque psoriasis, enthesitis-related arthritis and polyarticular juvenile idiopathic arthritis.

“The positive CHMP opinion for ABP 501 marks the first time an adalimumab biosimilar has been recommended for approval in the EU,” said Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen, “This represents another significant milestone for our biosimilars portfolio and is an important step in our effort to develop high-quality biologic medicines for patients suffering from chronic inflammatory diseases.”

Backed By Trial

The Marketing Authorization Application (MAA) submission for ABP 501 was based on a comprehensive data package supporting biosimilarity to adalimumab based on analytical, pharmacokinetic and clinical data, including results from two Phase-3 studies conducted in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis patients. Amgen in the press release noted that the Phase-3 studies each met their primary endpoint showing no clinically meaningful differences to adalimumab. Safety and immunogenicity of ABP 501 were also comparable to adalimumab.

Way Forward

CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). If approved, a centralized marketing authorization will be granted that will be valid in the 28 countries that are members of the EU. Norway, Iceland, and Liechtenstein, as members of the European Economic Area (EEA), will take corresponding decisions on the basis of the decision of the EC. ABP 501 was approved in the United States by the US Food and Drug Administration (FDA) on September 23, 2016, and is known by the brand name AMJEVITA™ (adalimumab-atto).

About ABP 501

ABP 501 is a biosimilar candidate to adalimumab, an anti-TNF-α monoclonal antibody, which is approved in many regions for the treatment of several inflammatory diseases. The active ingredient of ABP 501 is an anti-TNF-α monoclonal antibody that has the same amino acid sequence as adalimumab. AMJEVITA will be delivered in prefilled syringe and autoinjector presentations to support dosing in each of the approved indications.

Stock Performance

At the closing bell, on Friday, January 27, 2017, Amgen’s stock rose 2.73%, ending the trading session at $157.16. A total volume of 4.88 million shares were traded at the end of the day, which was higher than the 3-month average volume of 4.21 million shares. In the last month and previous twelve months, shares of the Company have advanced 5.93% and 8.73%, respectively. Moreover, the stock gained 7.49% since the start of the year. The stock is trading at a PE ratio of 15.70 and has a dividend yield of 2.93%.

Earnings Alerts: Amgen will hold a conference call on February 02, 2017 at 2:00 PM PT to discuss its Q4 2016 financial results.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453793

LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. blog coverage looks at the headline from Enbridge Inc. (NYSE: ENB) and Midcoast Energy Partners, L.P. (NYSE: MEP). Enbridge announced on January 27, 2017, that it has entered into a definitive agreement with Midcoast Energy Partners to acquire all of the outstanding publicly held common units of Midcoast Energy in cash, for $8 per unit or an aggregate transaction value of $170.2 million, taking it private. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

Today, AWS is promoting its blog coverage on ENB and MEP. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=ENB

http://www.activewallst.com/registration-3/?symbol=MEP

The Agreement

The agreement comprises of a definitive merger agreement between Midcoast Energy and Enbridge Energy Company, an indirect subsidiary of Enbridge. Subject to the terms of the agreement, the transaction price represents a 5.5% premium to the trailing 30-day volume weighted average of Midcoast Energy’s common units as of January 26, 2017. The transaction is expected to close in Q2 2017. Upon closing, Midcoast Energy will cease to be a publicly traded partnership.

Midcoast Distribution

Midcoast Energy announced that the board of directors of its general partner declared a quarterly cash distribution of $0.3575 per unit on all of its outstanding common and subordinated units, for the quarter ended December 31, 2016. The approved distribution remains unchanged from the previous quarter. The distribution is payable on February 14, 2017, to unit-holders of record at the close of business on February 07, 2017. Upon the payment of the distribution for the quarter ended December 31, 2016, it is anticipated that the subordination period with respect to Midcoast Energy subordinated units owned by Enbridge Energy Partners, L.P. (NYSE: EEP) will end and the subordinated units will convert into common units on a one-for-one basis. Once the subordinated bonds are converted, Enbridge Energy Partners, will own 52% of Midcoast Energy’s outstanding common units. Enbridge Inc. currently holds a 21.1% stake in Enbridge Energy Partners, which primarily owns and operates crude oil and NGL in the United States.

Enbridge’s Growth Strategy

Enbridge Energy Partners and Enbridge Inc. announced on August 08, 2016, an agreement where Enbridge Energy forms a partnership with Marathon Petroleum Corporation. The joint venture will be controlled by both the Companies where Enbridge Energy will hold 75% stake and Midcoast Energy will reap profits upon its 25% stake in the joint venture. The purchase price was $1.5 billion in cash and the transaction closed in the third quarter 2016. Viewed as a strategic growth move, the acquisition offered the Company to execute development in the segment by accessing a pipeline system which will transport crude oil from the Bakken formation in North Dakota markets.

This agreement was closely followed by the formation of the largest energy infrastructure Company in North America. Enbridge formed an agreement with Spectra Energy Corp. (NYSE: SE), hence bringing in a stock-for-stock transaction, with an enterprise value worth $127 billion on September 06, 2016.

Stock Performance

At the closing bell, on Friday, January 27, 2017, the stock closed the trading session at $43.03, falling 3.02% from its previous closing price of $44.37. A total volume of 4.77 million shares have exchanged hands, which was higher than the 3-month average volume of 2.16 million shares. Enbridge’s stock price advanced 0.56% in the last month, 12.21% in the past six months, and 35.74% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have gained 2.16%. The stock is trading at a PE ratio of 28.20 and has a dividend yield of 4.10%. The net market capital for the firm stood at $40.56 billion.

Last Friday, Midcoast Energy Partners’ stock slipped 4.57%, ending the trading session at $8.35. A total volume of 1.92 million shares were traded at the end of the day, which was higher than the 3-month average volume of 87.88 thousand shares. In the last month and previous six months, shares of the Company have surged 21.01% and 19.96%, respectively. Moreover, the stock surged 18.44% since the start of the year. The stock has a dividend yield of 17.13%. The net market capital for the firm was $385.37 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453795